EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
about
Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderThe interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and diseaseEarly response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profileLMP1+SLAMF1high cells are associated with drug resistance in Epstein-Barr virus-positive Farage cells.Newly emerging therapies targeting viral-related lymphomas.Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.The TRAIL to viral pathogenesis: the good, the bad and the uglyThe Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesGermline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis.Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.Epstein-Barr virus: evasive maneuvers in the development of PTLD.Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients.Cross-regulation between herpesviruses and the TNF superfamily membersEpstein-Barr virus, rapamycin, and host immune responses.Viral strategies for the evasion of immunogenic cell death.The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide.Epstein-Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?Virus Infection and Death Receptor-Mediated Apoptosis.
P2860
Q26859114-174F2AD9-7341-4E6A-8D50-CEF656A7DB26Q26998401-A7908615-0D79-4D6F-A59A-20F943FC1BCEQ33409443-7C11AD1F-2F3A-4782-B633-016C0FA63319Q33551720-87B29479-1D0F-4C62-9B8E-F1FF0C9A05B8Q33648588-12A221B2-4BFD-43F9-91D7-74B55DDED546Q33699201-B4C7FD9A-7486-4A92-B12E-901B33DCF0A2Q34067506-2CD6D551-14B1-4C72-97DA-98B0565141C9Q34180551-09C87F5B-754C-4FAD-8F3D-6DAAB401D214Q35146349-9BA2CE87-9362-4E42-B878-6972F3CE43C1Q35172090-CC627927-527C-4013-9BA9-B24EBB170AEAQ35739113-4E413C78-B0D3-4240-A9F0-6439C9031F49Q36199894-1E54D6B1-F1E8-45F7-9C87-FA98849B57DCQ36710230-B1693B33-3343-4917-A2C7-EC42AE6DECEDQ37272726-A24F9E20-2DEC-47A4-AB3B-0F49076D19C7Q37307520-4BB42935-B3FC-4C61-BE31-461163BB0149Q37342546-948D1DB2-EFF1-4869-8CCE-3D255284B39DQ37740184-EB4026F0-8BB9-4D82-B734-9DCF1F789889Q39219487-6BE1FB2D-9AAD-4D78-B38A-11409593AE80Q39633184-90361B23-9E52-4F81-800A-02B9E05AF616Q39782283-6B8A21B3-981A-4390-B59A-8BE719DB294BQ45325588-E75A0F5A-C84B-4147-9E5E-F8501FB4B33C
P2860
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@en
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@nl
type
label
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@en
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@nl
prefLabel
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@en
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@nl
P2093
P1476
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
@en
P2093
Andrew L Snow
Carlos O Esquivel
Olivia M Martinez
Sheri M Krams
Stacie L Lambert
Yasodha Natkunam
P304
P356
10.4049/JIMMUNOL.177.5.3283
P407
P577
2006-09-01T00:00:00Z